This finding prompted us to conduct a clinical trial in GBM patients who are newly diagnosed and treated with olaparib in adjuvant to RT or RT + TMZ depending on MGMT status stratification (phase 1, PARADIGM-2). The gene discussed is MGMT; the disease is glioblastoma.